[{"company":"Emergex Vaccines Holding","sponsor":"Vickers Venture Partners","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Emergex completes \u00a38.4m Series A vaccines funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Emergex Vaccines Holding"},{"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Begins Phase II COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"4D Pharma"},{"company":"Vaccitech Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participant Dosed in Phase 1 Clinical Study with VTP-300 Immunotherapeutic to Treat Chronically Infected Hepatitis B Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Vaccitech Oncology"},{"company":"GSK","sponsor":"Medicago","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK and Medicago Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Candidate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"GSK"},{"company":"Fujifilm Diosynth Biotechnologies","sponsor":"U.S Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Fujifilm Diosynth Biotechnologies"},{"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I Clinical Trial Initiated for Monoclonal Antibody Combination for the Prevention and Treatment of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AstraZeneca"},{"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$486.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's COVID-19 Long-Acting AntiBody Combination AZD7442 Rapidly Advances into Phase III Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AstraZeneca"},{"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Begins Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Tiziana Life Sciences"},{"company":"Open Orphan","sponsor":"Codagenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Open Orphan Receoves MHRA Approval for Nasal COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Open Orphan"},{"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sci PLC - Completion of Foralumab Clinical Trial in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Tiziana Life Sciences"},{"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Oxford to Study Nasal Administration of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"University of Oxford"},{"company":"Emergex Vaccines Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Emergex Vaccines Holding"},{"company":"Scancell","sponsor":"University of Cape Town Lung Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in COVIDITY Phase 1 Clinical Trial In South Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Scancell"},{"company":"Pneumagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Pneumagen"},{"company":"Emergex Vaccines Holding","sponsor":"Molecular Biology Institute of Parana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex Vaccines Signs Heads of Terms for A Collaboration with Molecular Biology Institute of Parana (IBMP) in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Emergex Vaccines Holding"},{"company":"SpectrumX","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpectrumX Reaches Partnership Agreement on Human Volunteer Study for Ground-breaking Respiratory Infection Drug Candidate SPX-001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"SpectrumX"}]
Details:
Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001.
Lead Product(s):
SPX-001
Therapeutic Area: Infections and Infectious Diseases
Product Name: SPX-001
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
September 20, 2022
Details:
The agreement initially focuses on Emergex’s Dengue vaccine candidate and also includes the shared development and commercialisation of COVID-19 and Chikungunya vaccine candidates.
Lead Product(s):
LD PepGNP-Dengue Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Molecular Biology Institute of Parana
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
July 01, 2022
Details:
Top line data from the trial show that Neumifil is well tolerated with no dose limiting toxicities and a safety profile that strongly supports further development. No serious adverse events were reported at any of the doses evaluated in the study.
Lead Product(s):
Neumifil
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 12, 2022
Details:
SCOV1 and SCOV2 are based on a modification of Scancell's ImmunoBody® DNA vaccine technology to induce high avidity T-cell immune responses against both N and S viral antigens. COVIDITY clinical trial assess safety and immunogenicity of SCOV1 and SCOV2.
Lead Product(s):
SCOV1,SCOV2
Therapeutic Area: Infections and Infectious Diseases
Product Name: Covidity
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
University of Cape Town Lung Institute
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 05, 2021
Details:
This double-blind, randomised and comparator-controlled study will evaluate the safety of the investigational vaccine, PepGNP-Dengue.
Lead Product(s):
PepGNP-Dengue
Therapeutic Area: Infections and Infectious Diseases
Product Name: PepGNP-Dengue
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 30, 2021
Details:
The Phase I trial, which will enrol 30 healthy volunteers aged 18–40, will investigate the level of immune system responses generated by the ChAdOx1 nCoV-19 using this delivery technique, as well as monitoring safety and for any adverse reactions.
Lead Product(s):
ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases
Product Name: AZD1222
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 25, 2021
Details:
The scientific approaches underlying this clinical study could potentially be effective against SARs, MERS, and all variants of coronaviruses. Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated.
Lead Product(s):
Foralumab,Dexamethasone
Therapeutic Area: Infections and Infectious Diseases
Product Name: NI-0401
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 04, 2021
Details:
The study will assess the safety and immunogenicity of a single-dose nasal vaccine candidate COVI-VAC in 48 healthy young adult volunteers.
Lead Product(s):
COVI-VAC
Therapeutic Area: Infections and Infectious Diseases
Product Name: COVI-VAC
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Codagenix
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 14, 2020
Details:
Trial arranged in collaboration with Harvard Medical School and Dr. Howard Weiner. A patent application was filed in July 2020 to protect the potential use of nasally administered Foralumab to treat COVID-19 either alone or in combination with other anti-viral drugs.
Lead Product(s):
Foralumab,Dexamethasone
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 02, 2020
Details:
AstraZeneca plans to supply up to 100,000 doses of AZD7442 starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.
Lead Product(s):
AZD7442
Therapeutic Area: Infections and Infectious Diseases
Product Name: AZD7442
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
BARDA
Deal Size: $486.0 million
Upfront Cash: Undisclosed
Deal Type: Agreement
October 09, 2020
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
